July 17, 2009Journal of ImmunotherapyOpen Access

Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor

View Full Paper

Ask AI

Bookmark

Engineered anti-CD19 chimeric antigen receptor T cells specifically eliminate primary chronic lymphocytic leukemia cells and release interferon-γ upon target binding.
Anti-CD3 OKT3 stimulation applied before transduction and at day 7 drove robust proliferation of patient-derived T cells, even following intensive chemotherapy.
Establishing a GMP-compliant gammaretrovirus producer cell line facilitates clinical translation for patients with advanced B cell malignancies; in vitro model limits apply.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical study demonstrates specific killing of chronic lymphocytic leukemia cells by anti-CD19 CAR T cells, highlighting a scalable protocol for clinical translation.

Cite This Study

Kochenderfer et al. (2009) studied this question.

synapsesocial.com/papers/68f8a73924b0bc2d85900684 https://doi.org/10.1097/cji.0b013e3181ac6138

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates specific killing of chronic lymphocytic leukemia cells by anti-CD19 CAR T cells, highlighting a scalable protocol for clinical translation.

Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor

Key Points

Discussion

Implication

Cite This Study

Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider